Antiplatelet therapy is a mainstay of cardiovascular therapy and is well established in clinical routine. Recently, the potential risk of solid cancers with P2Y 12 inhibitor therapy has been an issue of growing interest. The alleged association primarily originated from the findings of an US Food and Drug Administration (FDA) review of the randomized controlled TRITON-TIMI 38 trial and the following results of the DAPT trial. The higher risk of cancer was predominately observed with the newer, more potent P2Y 12 inhibitors and in the setting of prolonged dual antiplatelet therapy (DAPT). Current European Society of Cardiology (ESC) Guidelines suggest consideration of prolonged DAPT beyond the recommended duration of 6 months in stable coronary artery disease and 12 months in acute coronary syndrome if ischaemic risk prevails over the risk of bleeding. Several trials, studies and meta-analyses have addressed the potential interplay of cancer and P2Y 12 inhibition since then. The effect of P2Y 12 inhibition on cancer has been investigated extensively in basic research as well. In this review, we summarize current available evidence of cancer risk with P2Y 12 inhibitor therapy and discuss the resulting clinical implications.
Introduction
Recently, the association of P2Y 12 inhibitor therapy and cancer has been a topic of major debate.
1,2 P2Y 12 inhibitors have been used for years in a variety of cardiovascular and cerebrovascular settings with great success. Their efficacy in the secondary prevention of ischaemic events is well established and confirmed by several large-scale, randomized controlled trials (RCTs). How did the concern of cancer risk in patients treated with P2Y 12 inhibitors come to attention of the research community? The data from the randomized, controlled TRITION-TIMI 38 and DAPT trial initially raised the question of a potential interplay between cancer and the use of P2Y 12 inhibitors. Within this editorial, we critically evaluate current available literature regarding the concern of cancer risk in patients treated with P2Y 12 inhibitors and aim to draft a conclusive statement directed at the treating physician.
Clinical trials which initially raised the concern of cancer risk with P2Y 12 inhibitors
The randomized controlled, TRITON-TIMI 38 trial compared prasugrel with clopidogrel as part of dual antiplatelet therapy (DAPT; 6-15 months) in patients with moderate-to high-risk acute coronary syndrome (ACS) ( Table 1) . 3 Prasugrel treatment was associated with a significant reduction of ischaemic cardiovascular events at the cost of significant bleeding hazards. Upon the analysis of the FDA review of the TRITO-TIMI 38 trial, a higher incidence of cancer [1.5% vs. 1.0%, hazard ratio (HR) 1.6; P = 0.0013] and cancer-related mortality (0.49% vs. 0.31%, risk ratio (RR) 1.57; P = non-significant) in patients on prasugrel compared with clopidogrel was reported. 4 6 If DAPT was well tolerated for 12 months without any adverse bleeding or ischaemic events, patients were randomized to an additional 18 months of DAPT with clopidogrel or prasugrel on top of aspirin. While there was a significant reduction of ischaemic cardiovascular events, prolongation of DAPT also resulted in a higher all-cause mortality, which was not related to bleeding hazards. Interestingly, a statistically nonsignificant, but higher incidence of new solid cancers was observed in the group of prolonged DAPT compared with standard DAPT (2.0% vs. 1.6%, P = 0.14) as was a significantly increased rate of malignancyrelated mortality (0.62% vs. 0.28%, P = 0.02). The higher incidence of new cancer cases was predominantly seen in the prasugrel group, while a higher malignancy-related mortality was more common in the clopidogrel group. The PEGASUS-TIMI 54 trial prospectively evaluated the effect of prolonged DAPT on clinical outcomes in patients with a history of myocardial infarction (MI). 7 Patients with a prior MI within the past 1-3 years, were randomized to ticagrelor 90 mg b. were event-free after 1 year of DAPT (25 938 patients). Data was generated from the Korean Outcomes Registry Evaluating Antithrombotics (KOREA). The investigators reported a higher cancer incidence (4.15% vs. 4.04%, P = 0.005) and similar all-cause mortality with 30-month DAPT compared with 12-month DAPT. These findings of higher solid cancer incidence and malignancyrelated mortality were observed predominantly in the setting of extended DAPT, hence questioning the recommendation of prolongation of DAPT in patients with high ischaemic risk. There are several hypotheses trying to explain the observed paradox association with P2Y 12 inhibition and cancer risk. The newer, more potent P2Y 12 inhibitors (ticagrelor and prasugrel) as well as a longer duration of DAPT (> _12 months) cause significantly more bleeding events, which may lead to an early detection of otherwise non-diagnosed gastrointestinal, urological, and genitourinary malignancies leading to ascertainment bias. Another reason for the observed cancer association may lie in the nature of chance. These RCTs were not powered to detect differences in cancer-related events or mortality. Levels of statistical significance were mostly low or not met at all, and the absolute differences in the number of index cancer cases in these trials were small. Another confounder in the assessment of P2Y 12 inhibitor effects, is the common practice of combined prescription with aspirin, which itself may have cancer-protective entities. 9 
Basic research studies
The P2Y 12 receptor is a seven transmembrane receptor, mainly but not exclusively found on platelets and regulates several critical steps 10 The majority of the currently available basic research data supports the safe use of P2Y 12 inhibitors with regards to cancer risk and even points towards a potential beneficial effect on tumourigenesis and metastasis. P2Y 12 inhibition has been shown to reduce interaction of platelets with cancer cells in tumour infested mice, leading to an inhibition of tumour adhesion and metastasis.
11 P2Y 12 inhibitors also decrease levels of vascular endothelial growth factor in platelet-rich plasma of healthy individuals, leading to an inhibition of angiogenesis, 12 and they augment cytotoxicity of cisplatin in 4T1 breast cancer cell lines, mediated by up-regulation of hypoxia-inducible factor 1-alpha, which is a key factor in the development of resistance to cytotoxic therapy.
13
P2Y 12 inhibitors decrease levels of Ki67, an important proliferation marker, in rodent models of ovarian cancer, resulting in a reduction of the primary tumour.
14 Other studies, however, claim a contrary effect. A study of combined clopidogrel and aspirin treatment in 4T1 metastatic breast cancer-bearing mice, has shown a promotion of cancer malignancy and mortality, induced by increased vascular mimicry. The same study, however, also reported that the inhibition of platelet function exhibited a protective effect against pulmonary metastasis. 15 Two preclinical, animal studies found an increase of hepatocellular carcinoma and uterine adenocarcinoma incidence for prasugrel and ticagrelor, respectively. These findings, however, were observed under much higher supraphysiological doses than clinically used and have been classified as not clinically relevant.
16,17
Further clinical evaluation Table 2) . 18 One meta-analysis focused on cancer-related adverse events and included four trials (37 835 patients), while the second one assessed cancer-related death in five trials (40 855 patients). Both meta-analyses rejected the hypothesis of cancer association in patients on DAPT with clopidogrel. Hence, the FDA concluded that clopidogrel has no effect on cancer.
A post hoc analysis of the TRILOGY trial, which compared DAPT with clopidogrel vs. DAPT with prasugrel in patients with ACS who did not undergo revascularization, was performed to investigate the association of the P2Y 12 inhibitor prasugrel and cancer. History of prior malignancy was carefully assessed and suspected neoplasm events were classified and judged according to a predefined protocol. Incidence of malignancy was similar among patients treated with prasugrel compared with clopidogrel (1.8% vs. 1.7%, P = 0.79) and low overall (1.8% of patients on DAPT). 19 Moreover, several other RCTs, including the CAPRIE, 20 CHARISMA, 21 and PLATO 22 trial, showed no significant association of cancer risk with P2Y 12 inhibitors. Leader et al. conducted a population-based cohort study including 183 912 subjects, in whom more than 21 000 cases of cancer were diagnosed. Association of cancer incidence with DAPT (clopidogrel plus aspirin), aspirin monotherapy, or no antiplatelet therapy was assessed. In contrast to the cancer registry study by Serebruany et al., 8 a reduction of cancer risk in patients with DAPT compared with aspirin monotherapy (HR 0.46, P = 0.006) or no antiplatelet therapy was demonstrated. 23 Another meta-analysis assessed cancer event rates and mortality with clopidogrel and prasugrel in 282 084 patients from six RCTs and three retrospective cohort studies. No significant differences with regards to cancer event rates and mortality were observed in patients with clopidogrel and aspirin compared with aspirin monotherapy or no antiplatelet therapy. These results remained persistent for patients with a DAPT regime including prasugrel. 5 More recently, a patient-level meta-analysis has been published comparing prolonged DAPT with clopidogrel to short or no clopidogrel on the background of aspirin in patients with cardiovascular or cerebrovascular disease. 24 Data was generated from six randomized trials, including 48 817 patients. No significant differences in all-cause mortality or cancer were observed between groups. Several other metaanalyses and registry studies have also confirmed the safe use of P2Y 12 inhibitors with regards to cancer risk. 25, 26 Summary and conclusion
In conclusion, considering the evidence available we can cautiously assume that P2Y 12 inhibitor therapy is safe with regards to cancer risk. The concern of cancer association with P2Y 12 inhibition originates from the data of RCTs not powered to detect differences in cancer-related mortality or event rates. Since then several large-scale meta-analyses and registry studies have been performed, which almost exclusively rejected the hypothesis of cancer association with P2Y12 inhibitors. The results of these studies have to be interpreted with caution, however, as they are mostly based on clinical trials, which lack sufficient follow-up and collection of cancer-related adverse events. Basic research data point towards a potential beneficial effect of P2Y12 inhibition on cancer. Therefore, P2Y12 inhibitors should not be withheld from patients with a guideline-supported indication based on a theoretical cancer risk which is not currently substantiated by the scientific evidence available. Future trials of P2Y 12 inhibitors should be designed to accurately collect information on cancer incidence and cancer-related mortality in participants.
